Among the investigational therapies, sotatercept—a novel fusion protein and activin signaling inhibitor that restores balance in the TGF-β/BMPR2 axis—has shown encouraging preliminary results in adult PAH and is now under evaluation in pediatric trials for iPAH and HPAH. The gene discussed is TGFB1; the disease is pulmonary arterial hypertension.